Akèy › Kansè Metastatik › Massachusetts
Etid klinik pou Kansè Metastatik nan Massachusetts
65 etid pou Kansè Metastatik ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- ak 1 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05372614A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06625775A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05382559Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07222800A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05118789Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06302621Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Mass General Cancer Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06915753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- University of Massachusetts Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Massachusetts Chan Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07629960Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07227415Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT04585958A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06561685Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06311214AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07038343A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT04802759A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
Ap rekriteFaz 1
Laj 18 a 99 · Tout sèks · Mizajou Sep 1, 2026 · NCT06983743A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- Avenzo Therapeutics Recruiting Site, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07193511Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05687136FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05687110Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT05372640Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT05533697Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT07137416A Study of PYX-201 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT05720117A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07458347A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT06952010A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.